Wegovy by another name: what semaglutide is really called

The myth that Wegovy and Ozempic are interchangeable

A lot of people arrive at this page having read on social media that Ozempic and Wegovy are essentially the same thing. The active ingredient is identical (semaglutide) but the MHRA has licensed each product for a specific purpose, and that distinction is not a technicality. Ozempic (0.5mg, 1mg and 2mg injection) is licensed in the UK for type 2 diabetes management. Wegovy (2.4mg injection, now also available as a 25mg tablet) is licensed for weight management. Prescribing Ozempic for weight loss, or Wegovy for diabetes, would be off-label use requiring a specific clinical rationale.

The dose difference matters too. Ozempic's maximum dose is 2mg weekly; Wegovy's maintenance dose runs to 2.4mg weekly for the injection, and up to 25mg daily for the tablet. These are not the same product in different boxes. If someone offers you Ozempic for weight loss, it is worth pausing before accepting that as straightforward. A genuine prescriber will put you on the licensed product for the licensed indication. You can read more about how Wegovy compares to Ozempic for weight loss if that question has been on your mind.

The NHS is clear on this point: the NHS semaglutide medicines page separates the brands by their licensed use and does not present them as equivalent routes to the same outcome.

Rybelsus: the oral semaglutide that is not the Wegovy tablet

Here is where it gets slightly trickier. Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes, at doses of 3mg, 7mg and 14mg. The Wegovy tablet, approved by the MHRA on 11 June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management, uses doses of 1.5mg, 4mg, 9mg and 25mg. Different schedule, different licensed purpose, different product entirely.

If you have come across references to a 3mg or 14mg semaglutide tablet in the context of weight loss, those are Rybelsus strengths. They are not steps on the Wegovy tablet ladder. This matters for anyone researching options online, where the two products are sometimes blurred together. The Wegovy tablet's trial data (from the OASIS 4 phase 3 study) showed around 13.6% average weight reduction over 64 weeks versus placebo, rising to roughly 17% among participants who adhered fully to treatment throughout. Rybelsus was not studied for weight management and carries no such evidence base in that context.

Understanding what semaglutide's various names and branded products actually represent helps when you are trying to work out which one a clinic is offering you, and whether that matches your goal.

Why semaglutide gets so many names, and what that means in practice

Pharmaceutical companies brand the same molecule differently across indications partly for regulatory clarity and partly for commercial reasons. Novo Nordisk, the manufacturer of all three UK semaglutide products, needed separate marketing authorisations from the MHRA for each use. That process involves specific trial evidence for the specific population, so Wegovy's approval rests on STEP 1 and OASIS 4 data from people with obesity or overweight, not on the diabetes trials that support Ozempic and Rybelsus.

In practice, what this means for you is simple: when you are seeking treatment for weight management, the product you want is Wegovy. If a provider quotes you a different semaglutide brand for that purpose, ask which product they are actually prescribing and under what authorisation, and if you are unsure what that brand is actually called, our page covering another name for semaglutide explains the terminology clearly. Private treatment costs are worth understanding in context too, the Wegovy price comparison page sets out what the UK private market currently looks like.

Wegovy is a prescription-only medicine. A prescriber assesses your clinical picture before authorising it, BMI, weight-related conditions, medical history. That assessment exists because semaglutide is a potent medicine with a real side-effect profile (predominantly gastrointestinal: nausea, diarrhoea, constipation in the weeks after starting or increasing the dose). The Wegovy overview page covers the full licensed picture in the UK, including the new 7.2mg injection dose approved in January 2026.

Navigating the names when you are ready to ask about treatment

Wegovy, semaglutide, the weight-loss jab, patients use all of these, and our prescribers understand what is meant. What matters is that when treatment is prescribed, the paperwork, the pen or the tablet you receive carries the name of the product that has been assessed, approved and authorised for your situation. A broader look at semaglutide as a treatment class is useful background if you want to understand the mechanism before your consultation.

At nume, sorry. At this point it is worth knowing that our clinical team, led by our GPhC-registered Independent Prescriber, reviews every consultation personally on the day it is submitted. If you have questions about which product is right for you, or whether you are eligible, the FAQ page covers common queries, and you can reach us directly via the contact page. When you are ready, check your eligibility for a free consultation and a prescriber will assess your case, not a bot, not an automated system.